1. In this randomized-controlled trial, an mRNA-based vaccine was efficacious at preventing symptomatic infection with respiratory syncytial virus (RSV) involving one respiratory sign or symptom in 68.4% of participants. 2. The mRNA-based vaccine was associated with a higher rate of mild to moderate adverse events than placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: RSV
Though the novel coronavirus, as an “emergency,” has been widely categorized as “being over,” health care officials continue to urge caution in the “post-pandemic world,” especially during the winter and spring seasons.
With the arrival of winters, you need to guard yourself against common illnesses such as influenza, the common cold, bronchitis, pneumonia, stomach flu, dry eyes, and respiratory syncytial virus (RSV). Follow these health tips to prevent and treat these common irritants.